117 0 Kommentare Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Cash runway anticipated to be extended from Q2 2025 to Q4 2025
Data from multiple Phase 1 and 2 clinical trials expected in 2024

OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

“2024 promises to be another exciting year for Barinthus Bio, with multiple data readouts expected across our hepatitis B virus (HBV) infection, human papillomavirus (HPV) infection and prostate cancer programs, as well as the planned initiation of the first in human study of our SNAP platform-based candidate VTP-1000 in Celiac Disease,” said Gemma Brown, Chief Financial Officer of Barinthus Bio. “Given the encouraging preliminary data in HBV and HPV infection and to maximise value for our stakeholders, we are focusing resources and deferring the planned IND application for VTP-1100 in HPV cancer. As a result of this, as well as the strategic phasing of manufacturing across our pipeline to focus on progressing our Phase 2 trials, we anticipate that our cash runway has extended from Q2 2025 to Q4 2025."

Financial Update:

Cash and cash equivalents expected to be $142 million as of December 31, 2023.¹
Based on management’s current assumptions, we believe our cash and cash equivalents will fund our operations into the fourth quarter of 2025.
As of December 31, 2023, there were approximately 38.6 million ordinary shares issued and outstanding.

Anticipated 2024 Corporate Milestones:

H1 2024:

Initiate a Phase 1 clinical trial with VTP-1000 in Celiac Disease.
Announce final results from participants receiving VTP-200 in the Phase 1b/2 APOLLO (HPV001) trial evaluating the safety, immunogenicity and efficacy of VTP-200 in persistent HPV infection and low grade cervical lesions.
Announce interim data from HBV003, our Phase 2b trial evaluating additional dosing of VTP-300 and PD-1 inhibition timing in people with chronic hepatitis B infection.
Announce interim data from the first two arms of the Phase 2a AB-729-202 clinical trial evaluating VTP-300, NUC therapy and Arbutus’ imdusiran in people with chronic hepatitis B infection.